Rocket Pharmaceuticals
Rocket Pharmaceuticals
RCKT
NASDAQ
8.80
USD
3.53%
About
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia.
It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 677.6K |
| Three Month Average Volume | 17.6M |
| High Low | |
| Fifty-Two Week High | 32.525 USD |
| Fifty-Two Week Low | 15.27 USD |
| Fifty-Two Week High Date | 28 Dec 2023 |
| Fifty-Two Week Low Date | 12 Sep 2023 |
| Price and Volume | |
| Current Price | 18.85 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -14.53% |
| Thirteen Week Relative Price Change | -17.39% |
| Twenty-Six Week Relative Price Change | -43.85% |
| Fifty-Two Week Relative Price Change | -3.88% |
| Year-to-Date Relative Price Change | -46.89% |
| Price Change | |
| One Day Price Change | 0.37% |
| Thirteen Week Price Change | -11.59% |
| Twenty-Six Week Price Change | -38.26% |
| Five Day Price Change | 1.40% |
| Fifty-Two Week Price Change | 20.45% |
| Year-to-Date Price Change | -37.10% |
| Month-to-Date Price Change | -22.11% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 5.45593 USD |
| Book Value Per Share (Most Recent Quarter) | 4.22877 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 4.74368 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.5218 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.83646 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.92344 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.7938 USD |
| Normalized (Last Fiscal Year) | -2.8782 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.92344 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.7938 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.92344 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.7938 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.13343 USD |
| Cash Per Share (Most Recent Quarter) | 3.06547 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.83895 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.69626 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.31645 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 4.91% |
| Tangible Book Value (5 Year) | 21.28% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 62.52% |
| Total Debt (5 Year) | -12.59% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 9.00% |
| EPS Change (Trailing Twelve Months) | 15.25% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 5 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -257,625,000 |
| Net Debt (Last Fiscal Year) | -352,031,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 4 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 4 |
| Long Term Debt to Equity (Most Recent Quarter) | 5 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 8 |
| Current Ratio (Most Recent Quarter) | 8 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -211,388,000 |
| Free Cash Flow (Trailing Twelve Months) | -210,433,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 4 |
| Total Debt to Equity (Most Recent Quarter) | 6 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -43.93% |
| Return on Assets (Trailing Twelve Months) | -55.77% |
| Return on Assets (5 Year) | -35.26% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -50.01% |
| Return on Equity (Trailing Twelve Months) | -64.31% |
| Return on Equity (5 Year) | -40.67% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -47.67% |
| Return on Investment (Trailing Twelve Months) | -60.57% |
| Return on Investment (5 Year) | -37.49% |